Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020589 | 0.84 | RIPK1 (0.44) | CYP1A2CTSKCTSBCTSSSLC6A2 | |
| SCHEMBL4610682 | 0.74 | CYP1A2 (0.50) | CYP1A2CYP2A6CTSKCTSBCTSS | |
| SCHEMBL6019431 | 0.74 | CTSS (0.53) | CYP1A2CYP2A6CTSKCTSBCTSS | |
| SCHEMBL12802204 | 0.71 | CYP1A2 (0.46) | CYP1A2CYP2A6MMP1MMP9MMP13 | |
| SCHEMBL6019874 | 0.71 | CTSS (0.68) | CTSKCTSBCTSSMMP9 | |
| SCHEMBL6020489 | 0.71 | CTSS (0.45) | CTSKCTSBCTSSMMP1MMP9 | |
| SCHEMBL6020743 | 0.70 | MMP9 (0.53) | CTSKCTSBCTSSMMP9 | |
| SCHEMBL6021205 | 0.70 | MMP9 (0.53) | CTSKCTSBCTSSMMP9 | |
| SCHEMBL6021440 | 0.69 | CTSB (0.53) | CTSKCTSBCTSSMMP9 | |
| SCHEMBL6020196 | 0.69 | ALDH1A1 (0.46) | CTSKCTSSCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1575903-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES | Jerini AG (DE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004065353-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES | JERINI AG (DE) | 2004-08-05 | — | — | WO | claimed |
| WO-2004056755-A2 | COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES | JERENI AG (DE) | 2004-07-08 | — | — | WO | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1575903-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES | Jerini AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004065353-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES | JERINI AG (DE) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004056755-A2 | COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES | JERENI AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | CYP1A2 3116/4885CYP2A6 1265/4885CTSK 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.